Diabetes

Fragility fractures are a serious complication of type 1 and type 2 diabetes, but many clinicians who treat patients with diabetes are not aware of the increased risk of these fractures.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included encouraging results from the Next Generation Accountable Care Organization model; concerns that CMS' new billing rules will hurt the sickest patients; a study confirms the value of daily aspirin for patients with diabetes.

The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.

Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.

A leader at the Institute for Healthcare Improvement offers a framework for diabetes educators to embrace a shift in thinking about healthcare delivery.

Given the high cost of treating diabetes and the large population with prediabetes, prevention has become a point of focus. We’re taking a look back to 2017, when The American Journal of Managed Care® convened a panel of experts to discuss diabetes prevention and the use of technology.

Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center, explains why the Joslin Diabetes Center and the American Diabetes Association oppose the decision by the American College of Physicians to recommend a higher A1C target across the board.

Patients with type 2 diabetes and moderate renal impairment who took oral semaglutide in a phase 3a trial reported a larger reduction in glycated hemoglobin and more weight loss than patients taking placebo.

Three federal officials discussed the status of research, payer coverage, and referrals for the National Diabetes Prevention Program, as well as the rollout of the Medicare program for eligible seniors.

The rise of digital health alongside the transformation of reimbursement from fee-for-service to value-based care is allowing patients to fully participate in their own care, according to a leader with one of the top digital health companies in diabetes care.

Robert A. Gabbay, MD, PhD, FACP, chief medical officer and senior vice president at Joslin Diabetes Center, said health systems need people with the skill sets that diabetes educators possess to make the transition to a reimbursement system based on quality, prevention, and eliminating costs.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included, CMS allowing step therapy in Medicare Advantage plans in a bid to allow for drug price negotiation; larger practices with more resources, technology and care management processes have higher readmission rates than smaller practices; studies find that empagliflozin also reduces liver fat in patients with diabetes and nonalcoholic fatty liver disease.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

LifeScan, the diabetes division that Johnson & Johnson shed after ending US sales of its Animas insulin pump, will be the sole preferred provider of meters and testing strips for Express Scripts members in 2019.

States that ranked poorly are those with high rates of diabetes and obesity; those with high rankings have long-term commitments to getting people insured.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

The Joslin Clinical Guidelines are designed to be streamlined and disseminated as widely as possible, explained Robert A. Gabbay, MD, PhD, FACP, senior vice president and chief medical officer of Joslin Diabetes Center.

This week, the top managed care stories included a report that found quality issues and fraud in Medicare’s hospice program; the Trump administration expanded short-term health plans; cancer screening rates are falling short of targets.

The lead author of a study appearing this month in Diabetes Care said other data support his findings, pointing to the potential for the SGLT2 inhibitor empagliflozin to replace metformin as first-line therapy.

For the second year in a row, the average basic premium for a Medicare Part D plan will decline; a series of charts in The Wall Street Journal highlights what is driving US healthcare spending; taking a break from exercising can have metabolic consequences that linger for some people even after they return to their normal levels of exercise.